Скачать с ютуб In Vitro ADME & Drug-Drug Interaction Considerations for Toxicologists в хорошем качестве

In Vitro ADME & Drug-Drug Interaction Considerations for Toxicologists

Originally aired: April 2020 Presenter: Pallavi Limaye, Ph.D., DABT, XenoTech Director of Scientific Consulting with special Q&A guest, Brian Ogilvie, Ph.D., XenoTech Vice President of Scientific Consulting Originally scheduled to be presented at the canceled Society of Toxicology (SOT) 59th Annual Meeting & ToxExpo, our experts are bringing the tradeshow to you! Dr. Limaye will be discussing the intersection of ADME and toxicology in this webinar, followed by a live Q&A to address audience questions and comments. In vitro ADME and drug-drug interaction (DDI) investigations are early activities in the drug development process that are critical for framing downstream decision making. This ADME 101 webinar will provide insights at a high-level related to regulatory drivers, investigatory objectives, and practical concerns for such studies that are relevant to interested general toxicologists. Participants will gain insight as to the critical need and utility for in vitro ADME and DDI investigations as related to drug development. Regulatory expectations will be reviewed as will points of particular interest for enabling successful achievement of investigatory goals. Key concepts discussed in this webinar will include: Why run these studies? Predominant types of in vitro ADME & Drug-Drug Interaction (DDI) studies When to conduct these studies Areas of concern: Proper design & interpretation And other highlights and information... Download slides: https://www.xenotech.com/webinar-slid... Questions, comments and requests: https://www.xenotech.com/contact-us More information on our research services and test systems: https://www.xenotech.com Other previously aired webinars: https://www.xenotech.com/scientific-r... Upcoming webinar notifications: https://www.xenotech.com/newsletter-s... Request a webinar topic: https://www.xenotech.com/scientific-r... About the presenter: Pallavi Limaye completed her Ph.D. in Toxicology from The University of Louisiana in 2004 under the mentorship of Dr. Harihara Mehendale. She did her postdoctoral research in the Department of Pathology at University of Pittsburgh under the direction of Dr. George Michalopoulos and subsequently at the Department of Pharmacology, Toxicology, and Therapeutics at University of Kansas Medical Center under the mentorship of Dr. Curtis Klaassen. Pallavi joined XenoTech in 2011 as a Research Scientist and served as a study director for in vitro drug metabolism studies. In 2013, Pallavi joined Xenometrics LLC, now a part of Charles River Laboratories, as a Senior Scientist and served as a study director for regulated nonclinical IND- and NDA-enabling toxicology studies. From 2018 to 2020 Pallavi worked at MRIGlobal as a Principal Scientist and oversaw nonclinical toxicology and animal health studies, as well as contributed to containment research with select chemical agents. Recently Pallavi has joined XenoTech’s consulting team and provides input on drug-drug interaction study needs for the sponsors. Pallavi has published several original research articles in various journals (Hepatology, Toxicological Sciences among others) and has also contributed many book chapters in the field of toxicology and liver pathobiology. Pallavi is also actively involved in the scientific societies and currently serves on the Program Committee of American College of Toxicology and is the Vice President of Central States regional chapter of Society of Toxicology.